Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers

T. Kagawa, Masaya Iwamuro, S. Ishikawa, M. Ishida, S. Kuraoka, K. Sasaki, I. Sakakihara, K. Izumikawa, K. Yamamoto, S. Takahashi, S. Tanaka, M. Matsuura, T. Hasui, M. Wato, T. Inaba

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs). Aim: To compare the healing status of ESD-induced gastric ulcers and the incidence of post-ESD bleeding between subjects treated with vonoprazan for 5 weeks and those treated with PPIs for 8 weeks. Methods: Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection. Two controls per case of vonoprazan-treated group were matched with a margin of 20% in terms of ulcer size and a margin of 5 years in terms of their age. Results: Although a higher number of completely healed ulcers was observed in the PPI group (95/150, 63.3%) than that in the vonoprazan group (14/75, 18.7%; P < 0.001), the ulcer size reduction rates, which were 96.0 ± 6.7% in the vonoprazan group and 94.7 ± 11.6% in the PPI group, were not significantly different (P = 0.373). The post-ESD bleeding incidence in the vonoprazan group (1/75, 1.3%) was less than that in the PPI group (15/150, 10.0%; P = 0.01). The factors affecting post-ESD bleeding incidence were the type of acid secretion inhibitor (P = 0.016) and use of an anti-thrombotic agent (P = 0.014). Conclusion: Vonoprazan significantly reduced post-endoscopic submucosal dissection bleeding compared with PPIs.

Original languageEnglish
Pages (from-to)583-591
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume44
Issue number6
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Stomach Ulcer
Proton Pump Inhibitors
Hemorrhage
Ulcer
Incidence
Acids
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
Endoscopic Mucosal Resection
Helicobacter Infections
Helicobacter pylori
Potassium
Research Design

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. / Kagawa, T.; Iwamuro, Masaya; Ishikawa, S.; Ishida, M.; Kuraoka, S.; Sasaki, K.; Sakakihara, I.; Izumikawa, K.; Yamamoto, K.; Takahashi, S.; Tanaka, S.; Matsuura, M.; Hasui, T.; Wato, M.; Inaba, T.

In: Alimentary Pharmacology and Therapeutics, Vol. 44, No. 6, 01.09.2016, p. 583-591.

Research output: Contribution to journalArticle

Kagawa, T, Iwamuro, M, Ishikawa, S, Ishida, M, Kuraoka, S, Sasaki, K, Sakakihara, I, Izumikawa, K, Yamamoto, K, Takahashi, S, Tanaka, S, Matsuura, M, Hasui, T, Wato, M & Inaba, T 2016, 'Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers', Alimentary Pharmacology and Therapeutics, vol. 44, no. 6, pp. 583-591. https://doi.org/10.1111/apt.13747
Kagawa, T. ; Iwamuro, Masaya ; Ishikawa, S. ; Ishida, M. ; Kuraoka, S. ; Sasaki, K. ; Sakakihara, I. ; Izumikawa, K. ; Yamamoto, K. ; Takahashi, S. ; Tanaka, S. ; Matsuura, M. ; Hasui, T. ; Wato, M. ; Inaba, T. / Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. In: Alimentary Pharmacology and Therapeutics. 2016 ; Vol. 44, No. 6. pp. 583-591.
@article{0fbe25c7b20f4704a96af5dac8a09223,
title = "Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers",
abstract = "Background: Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs). Aim: To compare the healing status of ESD-induced gastric ulcers and the incidence of post-ESD bleeding between subjects treated with vonoprazan for 5 weeks and those treated with PPIs for 8 weeks. Methods: Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection. Two controls per case of vonoprazan-treated group were matched with a margin of 20{\%} in terms of ulcer size and a margin of 5 years in terms of their age. Results: Although a higher number of completely healed ulcers was observed in the PPI group (95/150, 63.3{\%}) than that in the vonoprazan group (14/75, 18.7{\%}; P < 0.001), the ulcer size reduction rates, which were 96.0 ± 6.7{\%} in the vonoprazan group and 94.7 ± 11.6{\%} in the PPI group, were not significantly different (P = 0.373). The post-ESD bleeding incidence in the vonoprazan group (1/75, 1.3{\%}) was less than that in the PPI group (15/150, 10.0{\%}; P = 0.01). The factors affecting post-ESD bleeding incidence were the type of acid secretion inhibitor (P = 0.016) and use of an anti-thrombotic agent (P = 0.014). Conclusion: Vonoprazan significantly reduced post-endoscopic submucosal dissection bleeding compared with PPIs.",
author = "T. Kagawa and Masaya Iwamuro and S. Ishikawa and M. Ishida and S. Kuraoka and K. Sasaki and I. Sakakihara and K. Izumikawa and K. Yamamoto and S. Takahashi and S. Tanaka and M. Matsuura and T. Hasui and M. Wato and T. Inaba",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/apt.13747",
language = "English",
volume = "44",
pages = "583--591",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers

AU - Kagawa, T.

AU - Iwamuro, Masaya

AU - Ishikawa, S.

AU - Ishida, M.

AU - Kuraoka, S.

AU - Sasaki, K.

AU - Sakakihara, I.

AU - Izumikawa, K.

AU - Yamamoto, K.

AU - Takahashi, S.

AU - Tanaka, S.

AU - Matsuura, M.

AU - Hasui, T.

AU - Wato, M.

AU - Inaba, T.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs). Aim: To compare the healing status of ESD-induced gastric ulcers and the incidence of post-ESD bleeding between subjects treated with vonoprazan for 5 weeks and those treated with PPIs for 8 weeks. Methods: Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection. Two controls per case of vonoprazan-treated group were matched with a margin of 20% in terms of ulcer size and a margin of 5 years in terms of their age. Results: Although a higher number of completely healed ulcers was observed in the PPI group (95/150, 63.3%) than that in the vonoprazan group (14/75, 18.7%; P < 0.001), the ulcer size reduction rates, which were 96.0 ± 6.7% in the vonoprazan group and 94.7 ± 11.6% in the PPI group, were not significantly different (P = 0.373). The post-ESD bleeding incidence in the vonoprazan group (1/75, 1.3%) was less than that in the PPI group (15/150, 10.0%; P = 0.01). The factors affecting post-ESD bleeding incidence were the type of acid secretion inhibitor (P = 0.016) and use of an anti-thrombotic agent (P = 0.014). Conclusion: Vonoprazan significantly reduced post-endoscopic submucosal dissection bleeding compared with PPIs.

AB - Background: Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs). Aim: To compare the healing status of ESD-induced gastric ulcers and the incidence of post-ESD bleeding between subjects treated with vonoprazan for 5 weeks and those treated with PPIs for 8 weeks. Methods: Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection. Two controls per case of vonoprazan-treated group were matched with a margin of 20% in terms of ulcer size and a margin of 5 years in terms of their age. Results: Although a higher number of completely healed ulcers was observed in the PPI group (95/150, 63.3%) than that in the vonoprazan group (14/75, 18.7%; P < 0.001), the ulcer size reduction rates, which were 96.0 ± 6.7% in the vonoprazan group and 94.7 ± 11.6% in the PPI group, were not significantly different (P = 0.373). The post-ESD bleeding incidence in the vonoprazan group (1/75, 1.3%) was less than that in the PPI group (15/150, 10.0%; P = 0.01). The factors affecting post-ESD bleeding incidence were the type of acid secretion inhibitor (P = 0.016) and use of an anti-thrombotic agent (P = 0.014). Conclusion: Vonoprazan significantly reduced post-endoscopic submucosal dissection bleeding compared with PPIs.

UR - http://www.scopus.com/inward/record.url?scp=85027948996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027948996&partnerID=8YFLogxK

U2 - 10.1111/apt.13747

DO - 10.1111/apt.13747

M3 - Article

C2 - 27471767

AN - SCOPUS:85027948996

VL - 44

SP - 583

EP - 591

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -